Detailed company information
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 06, 2026
Earnings Transcript for 2026 - Q1Released: May 12, 2026
Earnings Transcript for 2025 - Q4Released: Mar 19, 2026
Earnings Transcript for 2025 - Q3Released: Nov 13, 2025
Earnings Transcript for 2025 - Q2Released: Aug 08, 2025
Earnings Transcript for 2025 - Q1Released: May 12, 2025
Earnings Transcript for 2024 - Q4Released: Mar 27, 2025
Earnings Transcript for 2024 - Q3Released: Nov 10, 2024
Earnings Transcript for 2024 - Q2Released: Aug 09, 2024
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q4Released: Mar 19, 2024
Earnings Transcript for 2023 - Q3Released: Nov 09, 2023
Earnings Transcript for 2023 - Q2Released: Aug 08, 2023
Earnings Transcript for 2023 - Q1Released: May 12, 2023
Earnings Transcript for 2022 - Q4Released: Mar 23, 2023
Earnings Transcript for 2022 - Q3Released: Nov 12, 2022
Earnings Transcript for 2022 - Q2Released: Aug 14, 2022
Earnings Transcript for 2022 - Q1Released: May 08, 2022
Earnings Transcript for 2021 - Q4Released: Mar 23, 2022
Earnings Transcript for 2021 - Q3Released: Nov 11, 2021
Earnings Transcript for 2021 - Q2Released: Aug 10, 2021
Earnings Transcript for 2021 - Q1Released: May 12, 2021
Earnings Transcript for 2020 - Q4Released: Mar 24, 2021
💡 Across Q2 2025 earnings calls, companies reveal key pain points ideal for lightweight software solutions 🛠️ like workflow automation, AI tools, and dashboards, enabling quick wins with high impact across industries.
Read post
Dafinchi
